In a recent study, more than 40% of patients with relapsed or refractory germ cell tumors experienced a clinical benefit with cabozantinib.
The 2026 GU ASCO annual meeting featured a testicular cancer session and a presentation by Dr. Jennifer King discussing a ...
Scientists have uncovered a surprising way tumors turn the immune system to their advantage. Researchers at the University of Geneva found that neutrophils—normally frontline defenders against ...
Scientists at MIT and Stanford have unveiled a promising new way to help the immune system recognize and attack cancer cells more effectively. Their strategy targets a hidden “off switch” that tumors ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results